A magnetic mesoporous silica (SBA-15)-based dispersive solid phase microextraction was first proposed and introduced for simultaneous analysis of four cardiac glycosides (including deslanoside, lanatoside C, digoxin, and digitoxin) in human plasma coupled with HPLC-UV. In this study, magnetic C₁₈-modified SBA-15 (SBA-15/C₁₈/Fe₃O₄) was used as the extractant, which was prepared and characterized using a suite of techniques including Fourier transform infrared spectroscopy, transmission electron microscopy, N₂ adsorption-desorption, vibrating sample magnetometer, scanning electron microscopy, energy-dispersive X-ray spectroscopy and X-ray photoelectron spectroscopy. The influencing parameters of the extraction were investigated and optimized. The adsorption process of SBA-15/C₁₈/Fe₃O₄ followed the Langmuir isotherm and pseudo-second-order kinetic models. The adsorbent also exhibited excellent thermal and chemical stability, alongside good reusability. Under the optimum experimental conditions, the proposed method demonstrated satisfactory performance with good linearity (8-3200 ng/mL for deslanoside and 1.6-640 ng/mL for lanatoside C, digoxin and digitoxin with the correlation coefficients no less than 0.9987), high precision (0.8%

01 Aug 2025·SAGE Open Medical Case Reports

Heart failure temporally associated with tropicamide and phenylephrine eye drops in a premature infant: A case report and literature review

Article

Author: Sun, Jianhua ; Li, Xiang ; Chen, Xiafang ; Bu, Jun

This case report describes a rare instance of heart failure temporally associated with the administration of mydriatic eye drops during routine retinopathy of prematurity screening. A 36-week-old preterm infant developed acute tachypnea, tachycardia, and hepatomegaly shortly after receiving 0.5% tropicamide and 0.5% phenylephrine, and was subsequently diagnosed with heart failure, which responded well to intravenous deslanoside. Cardiac imaging later revealed multiple congenital anomalies, including an atrial septal defect, persistent left superior vena cava, and horseshoe lung, among others. No similar cardiovascular symptoms were observed during a subsequent screening using tropicamide alone, suggesting that phenylephrine may have contributed to the observed hemodynamic instability. This case illustrates the potential for severe cardiovascular complications associated with mydriatic agents in neonates with undiagnosed congenital heart defects. It underscores the need for individualized risk assessment, vigilant monitoring, and cautious application of mydriatic protocols to ensure patient safety in high-risk preterm populations.

01 Mar 2025·Infectious disorders drug targets

Screening and Identification of Natural Compounds as Potential Inhibitors of Glutamate Racemase, an Emerging Drug Target of Food Pathogen E. coli O157:H7: An In-silico Approach to Combat Increasing Drug Resistance

Article

Author: Mittal, Avneesh ; Khanna, Anoushka ; Sahoo, Sibasis ; Pandey, Archna ; Gupta, Samarth ; Faiza, Muniba ; Baweja, Renu ; Adhana, Sujata ; Chaudhry, Uma ; Kumar, Rajnish

Background::

Shiga Toxin-Producing Escherichia coli (E. coli O157:H7), capable of causing serious food-borne illnesses, is extensively studied and is known to be transmitted through animal reservoirs or person-to-person contact, leading to severe disease outbreaks. The emergence of antibiotic resistance in these strains, coupled with increased adverse effects of existing therapeutics, underscores the urgent need for alternative therapeutic strategies.

Objective::

This study aims to evaluate Glutamate Racemase (MurI protein) of the food-path-ogenic E. coli O157:H7 (EC MurI) as a novel drug target. Furthermore, the study seeks to identify new compounds with potential inhibitory effects against this protein.

Methods::

Using computational tools, the study identified inhibitor binding sites on EC MurI and identified relevant inhibitors capable of binding to these sites. Molecular docking tech-niques were employed to assess potential hits, and selected compounds were further analyzed for their structural activity and binding affinity to the protein.

Results::

The results of the study revealed that Frigocyclinone and Deslanoside, exhibited the best binding affinity with EC-MurI. Subsequent molecular dynamic (MD) simulations of the selected complexes indicated that both compounds were stable. This suggests that Frigocy-clinone and Deslanoside have the potential to serve as potent inhibitors of EC-MurI.

Conclusion::

In summary, this study highlights the urgent need for alternative therapies against food-pathogenic E. coli, focusing on E. coli O157:H7. Evaluation of Glutamate Race-mase as a drug target identified Frigocyclinone and Deslanoside as promising inhibitors. MD simulations indicated their stability, suggesting their potential as lead molecules for further research and treatment development.

100 Deals associated with Deslanoside

External Link

KEGG	Wiki	ATC	Drug Bank
D01240	Deslanoside	C01AA07	DB01078

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Arrhythmias, Cardiac	China	Jiangsu Jibeier Pharmaceutical Co. Ltd.	01 Jan 1982
Heart Failure	Japan	neo CritiCare Pharma Co., Ltd.	01 Mar 1955
Tachycardia	Japan	neo CritiCare Pharma Co., Ltd.	01 Mar 1955

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis